Trial Profile
A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs ST 400 (Primary) ; Busulfan
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Acronyms THALES
- Sponsors Sangamo Therapeutics
- 26 Jan 2023 Status changed from active, no longer recruiting to completed.
- 16 Dec 2021 Planned End Date changed from 1 Mar 2023 to 1 Nov 2022.
- 14 Dec 2021 Updated results assessing HbF expression in edited erythroid cells Thales trial (NCT03432364) presented at the 63rd American Society of Hematology Annual Meeting and Exposition